392 A phase 1a/b study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally dvanced or metastatic solid tumors and urothelial carcinoma
oleh: Jason Luke, Meredith McKean, Nehal Lakhani, Katherine Kacena, Alan Tan, Babar Bashir, David Aggen, Marissa Timothy, Sergio Santillana
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2021-11-01 |
Deskripsi
No description available for this item.